Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH

Key Inclusion Criteria: * Males and females 18 through 75 years of age. * Diagnosis of NASH based on NAFLD Activity Score (NAS) ≥ 4 with at least 1 point in each of steatosis, inflammation, and ballooning; Magnetic Resonance Elastography (MRE) showing kPa ≥ 2.61 or a multiparametric MRI (ie, LiverMultiScan) showing iron-corrected T1(cT1) \> 830 ms within 6 months of enrollment; or Transient elastography (TE, FibroScan) with liver stiffness ≥ 8.5 kPa and controlled attenuation parameter (CAP) \> 300 dB/m obtained within 3 months of enrollment. * Liver fat content ≥ 8% measured by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) during screening. * Diagnosis of T2DM for ≤ 10 years, with hemoglobin A1c ≤ 10.0% during screening, stable and controlled with diet or treatment for at least 3 months. Key Exclusion Criteria: * History of significant liver disease (eg, alcoholic liver disease, viral hepatitis, etc.) or liver transplant. * Presence of cirrhosis on any prior liver biopsy (stage 4 fibrosis). * Excessive consumption of alcohol. * Use of any insulin (injectable or inhaled), SGLT-2 inhibitor or glucagon-like peptide 1 (GLP-1, injectable or oral) products for \> 7 days within 3 months of screening. * Weight loss \> 10% in the 6 months prior to screening or \> 5% during screening. * Use of drugs historically associated with causing NAFLD for more than 4 consecutive weeks within 12 months prior to screening. * Concomitant use of drugs that are strong or moderate CYP3A4 inhibitors. * Concomitant consumption of grapefruit juice with the study drug. * History of diabetic ketoacidosis (DKA) within 1 month prior to the Screening Visit, or more than 2 episodes within 6 months prior to the Screening Visit. * History of \> 2 episodes of urosepsis or pyelonephritis within 5 years of screening.